BYSI Stock Summary and Trading Ideas (Beyondspring - | NASDAQ:BYSI)

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Beyondspring - trades on the NASDAQ stock market under the symbol BYSI.

As of September 16, 2026, BYSI stock price declined to $0.71 with 34,129 million shares trading.

BYSI has a beta of 0.11, meaning it tends to be less sensitive to market movements. BYSI has a correlation of 0.00 to the broad based SPY ETF.

BYSI has a market cap of $29.15 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BYSI traded as high as $4.00 and as low as $.57.

The top ETF exchange traded funds that BYSI belongs to (by Net Assets): VTI, VXF.

BYSI has underperformed the market in the last year with a return of -62.1%, while the SPY ETF gained +15.2%. In the last 3 month period, BYSI fell short of the market, returning -57.0%, while SPY returned +0.1%. However, in the most recent 2 weeks BYSI has outperformed the stock market by returning +17.6%, while SPY returned -1.0%.

BYSI support price is $.69 and resistance is $.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BYSI shares will trade within this expected range on the day.